An analog of the gastric inhibitory polypeptide (GIP) with synthetic modifications, Tirzepatide is believed to bind to the GLP-1 receptor. The alleged anti-inflammatory, cardioprotective, and weight-loss impacts of Tirzepatide are now the subject of ongoing research.
Tirzepatide Peptide: What is it?
Tirzepatide, or LY3298176, is a manufactured peptide that is thought to bind to and activate the GLP-1 and glucose-dependent insulinotropic polypeptide receptors. It is 39 amino acids long and mostly derived from GIP. To increase its longevity, a C20 fatty di-acid moiety has been added to the peptide.
How are GIP and GLP-1 defined?
In response to caloric intake, K cells in the upper small intestine release GIP, an incretin largely responsible for the insulinotropic incretin action. Although it is believed to decrease glucagon production in both hyperglycemic and normoglycemic situations, GLP-1 is an incretin in and of itself. Semaglutide and other GLP-1 analogs have been deemed impactful in the context of type 2 diabetes because the hormone is thought to decrease the rate of gastric emptying.
Compared to the impacts of giving either GIP or GLP-1 alone, the research suggests that Tirzepatide’s potential activation of both receptors may have a synergistic impact, leading to stronger insulin and glucagonostatic responses. Because of this, the peptide is considered a relevant candidate for further study in relation to obesity and type 2 diabetes.
Tirzepatide Peptide: Potential
As if its potential in the context of type 2 diabetes weren’t enough, Tirzepatide is also being investigated for its potential in the context of obesity and its cardioprotective action. Here is a rundown of the published findings for Tirzepatide, although many more studies are in progress, and will not be completed until at least the end of 2024.
Tirzepatide Peptide: Weight
Studies suggest that Tirzepatide may induce weight reduction by decreasing adipose inflammation and boosting adiponectin by activating GIP receptors in fat cells. This, in turn, is believed to decrease fat cell differentiation and increase energy expenditure.
Eli Lilly began the SURMOUNT development program in late 2022. Four worldwide phase 3 studies evaluated Tirzepatide’s potential in models of mass index (BMI) of 27 or above for evaluation.
With an average weight reduction of 16% Tirzepatide given for 72 weeks, the first experiment, which included more than 2,500 research models, suggested that Tirzepatide appeared to hold potential in inducing weight loss.
Tirzepatide Peptide: Diabetes
As previously stated, Tirzepatide has been hypothesized to improve glucose management and decrease animal food intake by regulating hypothalamic feeding centers via GIP signaling.
When compared to other diabetic compounds, such as Dulaglutide and Semaglutide, Tirzepatide has been posited by researchers to be potentially more influential in the regulation of blood sugar and may thereby have greater downstream implications in obesity. Regarding the reduction of hemoglobin A1c and the induction of weight loss in animal models of type 2 diabetes, Tirzepatide was hypothesized to be more effective than alternative compound Semaglutide in one study.
Tirzepatide Peptide: The Heart
Inflammation is a factor in the development and advancement of atherosclerosis; Tirzepatide is theorized to help alleviate this condition by selectively targeting GLP-1 receptors. Research has linked elevated adiponectin levels to a decreased risk of coronary heart disease, and Tirzepatide likewise appears to raise adiponectin levels.
Once-weekly presentations of Tirzepatide were speculated to improve lipoprotein biomarkers linked to insulin resistance and cardiovascular risk in a 26-week experiment of type 2 diabetic research models while possibly also lowering triglycerides, indicating a net reduction in the model’s risk of cardiovascular disease.
Cardiovascular outcomes data from a future experiment comparing Tirzepatide to Dulaglutide, a GLP-1 receptor agonist, might provide light on the relative merits of the two approaches. Find out more about the advantages of Tirzepatide by visiting Biotech Peptides.
Buying Tirzepatide Peptide Online
It is permissible to purchase Tirzepatide online for in vitro testing by qualified researchers and laboratory personnel. It is recommended that researchers refrain from buying Tirzepatide from peptide merchants online unless they explicitly specify that their peptides are strictly for research reasons.
Tirzepatide Peptide: Concluding Remarks
Tirzepatide peptide has been hypothesized to impact lipid profiles and influence animal models of obesity and type 2 diabetes.
Scientific data from the SURMOUNT experimental study program to evaluate the peptide’s impact have already been published, and more findings are due.
Strong data from various experimental studies suggest that this dual GIP/GLP-1 receptor agonist may be effective in various settings. Please remember that none of the compounds mentioned in this paper have been approved for human or animal consumption and should, therefore, not be purchased or utilised by unlicensed individuals outside of contained lab environments. This article served educational purposes only.
References
[i] Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D’Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3. PMID: 30473097; PMCID: PMC6308032. [ii] Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021;106(2):388-396. doi:10.1210/clinem/dgaa863 [iii] Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021;12(1):143-157. doi:10.1007/s13300-020-00981-0 [iv] Tate M, Chong A, Robinson E, Green BD, Grieve DJ. Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol. 2015;172(3):721-736. doi:10.1111/bph.12943 [v] Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021 Jul 10;398(10295):143-155. doi: 10.1016/S0140-6736(21)01324-6. Epub 2021 Jun 27. Erratum in: Lancet. 2021 Jul 17;398(10296):212. PMID: 34186022. [vi] Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647. [vii] Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Landó, L. F., Brown, K., Bray, R., & Rodríguez, Á. (2021, August 6). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (surpass-3): A randomised, open-label, parallel-group, phase 3 trial. The Lancet. [viii] Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 8;327(6):534-545. doi: 10.1001/jama.2022.0078. PMID: 35133415; PMCID:
